GlassScriptPhysician profile
William B Harley
NPI 1467402719
$307,243.81
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $20K · 2021: $33K · 2022: $64K · 2023: $83K · 2024: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $81K · Travel and Lodging: $26K · Food and Beverage: $7,422 · Consulting Fee: $2,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,640.00 |
| Travel and Lodging | $25,823.15 |
| Food and Beverage | $7,422.20 |
| Consulting Fee | $2,860.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $137,402.91 | 2019-2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $92,397.10 | 2019-2024 | Recarbrio, Pifeltro, Zerbaxa |
| Gilead Sciences, INC. | $68,480.53 | 2019-2024 | Biktarvy |
| Viiv Healthcare Company | $3,435.22 | 2019-2024 | Dovato, Cabenuva, Apretude |
| Allergan, INC. | $2,116.01 | 2019-2020 | |
| Abbvie INC. | $716.65 | 2019-2024 | |
| Janssen Biotech, INC. | $661.06 | 2019-2023 | Symtuza |
| Insmed, INC. | $431.07 | 2019-2024 | Arikayce |
| Janssen Products, LP | $337.52 | 2019-2022 | |
| Astellas Pharma US INC | $260.68 | 2019-2024 | Cresemba |
| Shionogi INC | $212.02 | 2021-2024 | Fetroja |
| Theratechnologies INC. | $174.73 | 2020-2024 | Egrifta, Trogarzo |
| Melinta Therapeutics, LLC | $161.86 | 2020-2021 | |
| Inspire Medical Systems, INC. | $120.33 | 2019 | |
| Comsort, INC | $100.00 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $83.70 | 2019-2020 | |
| Napo Pharmaceuticals INC | $65.04 | 2019 | |
| La Jolla Pharmaceutical Company | $33.49 | 2024 | Xacduro, Xerava |
| Pfizer INC. | $16.22 | 2022 | |
| Vyera Pharmaceuticals, LLC | $15.13 | 2019 | |
| Nabriva Therapeutics, Plc | $12.92 | 2020 | |
| Janssen Scientific Affairs, LLC | $9.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Harley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.